Evidence map›Paper›PMID 37421429›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

Empagliflozin reduces endoplasmic reticulum stress associated TXNIP/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells.

Marc-Antoine Campeau, Richard L Leask

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marc-Antoine CampeauDepartment of Chemical Engineering, McGill University, Montreal, QC, Canada.
Richard L LeaskDepartment of Chemical Engineering, McGill University, Montreal, QC, Canada. richard.leask@mcgill.ca.
McGill University · CA

Funding

Natural Sciences and Engineering Research Council of Canada RGPIN 2018-06161
6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proven to be of therapeutic significance for cardiovascular diseases beyond the treatment of type 2 diabetes. Recent studies have demonstrated the beneficial effects of SGLT2i on endothelial cell (EC) dysfunction, but the underlying cellular mechanisms remain to be clarified. In this study, we sought to understand the effect of empagliflozin (EMPA; Jardiance

Indexed as

Diabetes Mellitus, Type 2NLR Family, Pyrin Domain-Containing 3 ProteinApoptosisBenzhydryl CompoundsCarrier ProteinsEndoplasmic Reticulum StressEndothelial CellsGlucosidesHumansInflammasomesTunicamycinBenzhydryl CompoundsCarrier ProteinsempagliflozinGlucosidesInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinTunicamycinTXNIP protein, humanEmpagliflozin (EMPA)Endoplasmic reticulum stress (ER stress)NLR-family pyrin domain-containing 3 (NLRP3)Nuclear factor erythroid 2-related factor 2 (nrf2)Sodium/glucose cotransporter 2 (SGLT2) inhibitorSotagliflozin (SOTA)Thioredoxin interacting protein (TXNIP)

Identifiers

PMID37421429
OpenAlexW4383560009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.